•••••PROFILE
Training in biochemistry, pharmacology and oncology focused on the preclinical development of drugs (in vivo efficacy, tolerability and pharmacokinetics, identification of biomarkers, functional genomics and proteomics studies in vitro and in vivo for the identification of mechanisms of action).
Curious, analytical and creative. Demonstrated ability for troubleshooting and integration of new technologies. Good team player and respectful of the deadlines.
EDUCATION
••••• Ã ••••••••••Doctorate in Neurooncology
Laboratoire de neurosciences précliniques, INSERM U•••••, Université Joseph-Fourrier, CHU de Grenoble, France.
••••• Ã ••••• Master in Pharmacology
Institut de Pharmacologie de Sherbrooke, Faculté de médecine de l’Université de Sherbrooke, P.Q., Canada
••••• Ã ••••••••••Baccalaureate in Biochemistry
Faculté des sciences de l’Université de Sherbrooke, P.Q., Canada
PROFESSIONAL EXPERIENCE
••••••••••Laboratory of neurosurgery, CHU de Sherbrooke. : Research Assistant (maternity leave replacement). Study the role of cancer stem cells in the resistance and invasion of glioblastoma.
••••• Painceptor Pharma Corp, St-Laurent: Research manager of the in vivo group. Study the efficacy, tolerability and pharmacokinetics of anti- NGF and ASICs analgesic compounds in rat.
••••• Ecopia Biosciences, St-Laurent.: Study the mechanisms of action of the antitumoral compound ECO•••••: Involvement of EGFR-Ras and energy pathways.
••••• Laboratoires Aeterna, Ste-Foy: Study the mechanisms of action of the antiangiogenic compound Neovastat: Inflammatory response and matrix proteolysis.
••••• IPS Pharma, Fleurimont: Study the effects of a bradykinin B1 receptor antagonist on vascular permeability induced by diabetes in mice.
AWARDS
••••• Governor General’s Award
PATENTS
••••• European patent no. ••••• Gourdeau H, Ranger M, Berger F, ••••• B. Methods for administration of a farnesyl dibenzodiazepinone.
RESEARCH ASSISTANT IN NEUROSURGERY
• FUNCTIONS
- Expand stem cells from primary culture of patient’s glioblastoma
- Identify CD•••••+ cell by flow cytometry (FCM) and isolate this subpopulation by magnetic cell sorting (MACS)
- Implant the neurospheres in matrigel and study their invasion in real time with the olympus FSX•••••
- Real time quantitative PCR (Taqman and Sybr green)
- Design a program to automate the PCR with the epMotion robot.
- Manage the laboratory supply to ensure its proper functioning.
• ACCOMPLISHMENTS
- After updating the protocols in place since 2 years, I have been the first to reliably obtain stem cells in the laboratory.
RESEARCH MANAGER AT PAINCEPTOR :
• ACCOMPLISHMENTS
- Reorganize all the data bank generated since the last 3 years in preparation for the submission to the FDA.
- Implement the IDBS system in the group.
- Guide a phase I clinical study which came to be a success.
• FUNCTIONS
- Design efficacy, tolerability and pharmacokinetic.
- Manage the work of 3 laboratory technicians.
- Optimize pain models induced by formalin, carrageenan, capsaicin and sciatic nerve ligation.
- Optimize models to determine sedation (rotarod, exploration).
- Optimize oral absorption of compounds affected by intestinal PGP in rat and rabbit.
- Prepare the protocols and the reports.
- Present the evolution of the two projects in weekly meetings.
DOCTORATE THESIS IN NEUROONCOLOGY : PROJECTS REALIZED
••••• Genomic and proteomic functional study of the antiangiogenic effect of Neovastat on mice glioblastoma.
• Discovery and validation of the importance the fibrinolytic system in the antiangiogenic efficacy of Neovastat for the treatment of mice glioblastoma.
&#•••••; Development, optimization and validation of subcutaneous and intracerebral mice glioma models
&#•••••; In vivo efficacy studies by chronic treatments; Evaluation of survival and tumor histology
&#•••••; Stable gene transfection of PAI••••• using lentivirus
&#•••••; Immunohistochemistry (GFAP, vWF) and Zymography (tPA, uPA, PAI•••••)
&#•••••; Transcriptionnal analysis by microarray of tumor tissues and endothelial cells in vitro
&#•••••; Great contribution to the identification of the mechanisms of action of Neovastat and of its active molecules.
• Pharmacokinétic of Neovastat in human and mouse serum following oral absorption
• Proteomic analysis of serum and tumor tissues by SELDI-TOF to identify biomarkers of efficacy.
&#•••••; Good knowledge of the Ciphergen technology
••••• Pharmacologic study of the compound ECO•••••
• Optimization the therapeutic regimen for the initiation of a phase I trial in human
&#•••••; Expertise for the gavages and intravenous injections
&#•••••; Evaluation of acute and chronic toxicity
• Transcriptomic study of the compound on mice glioblastoma in situ
&#•••••; Proposition of mechanisms of action involving the peripheral benzodiazepine receptor (PBR) and Ras in the EGFR pathway. Identification of complete networks of genes involved in the energy metabolism pathway and resistance to apoptosis.
MASTER IN PHARMACOLOGY
Pharmacologic study of the compound R•••••
• Effect of R••••• on vascular permeability and hyperalgesia induced by diabetes mellitus in mice : implication of the bradykinin B1 receptor
&#•••••; Induction and diagnosis of experimental diabetes in mice and rats
&#•••••; Model of plasma extravasation
&#•••••; Tail flick et hot plate test
Computer skills: Computer assembly, Windows and network
installation,
Software: Ciphergen, Agilent, Cellquest, Nanodrop,
epMotion, Pathway Assist, GraphPad, IDBS
and office.
Written and spoken languages: French and English
Hobbies and interests: Alpine skiing, tennis, golf, camping, work
out, martial arts, cinema, role playing.
